Eleusis Going Public via Silver Spike SPAC Merger for ~$446M
Shots:
- Eleusis signs a SPAC merger with Silver Spike for an enterprise value of ~$446M, $287.5M in gross proceeds from SPKB’s trust account, Eleusis shareholders & other investors will receive ~14% as an enterprise value of the combined company. The transaction is expected to close in Q2 or Q3’22
- Eleusis’s ELE-Psilo is a psilocybin-based drug, formulated for IV infusion to treat depression & is expected to enter the P-I trial in 2022. Eleusis will secure funds to expand its psychedelic drug therapy globally through its Andala subsidiary
- The current owners of Eleusis will obtain ~49% ownership of the combined company. The new company will trade on NASDAQ under the ticker “ELEU”
Ref: Businesswire | Image: Medcity News
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com